Abzena Capacity Update April 2025: Large Molecule Development

Cell line development (CLD) is the seminal process in the development of biologics. At the heart are cell lines that can deliver the critical quality attributes (CQAs) necessary to impart the appropriate functionality. They also must grow well in high-density culture and in serum-free commercial media for extended periods of time, provide productivity at levels that reduce cost of goods (COGs), and have the appropriate genetic stability during production to yield a consistent product. There are several cloning strategies available to achieve this, but Abzena’s AbZelectPRO™, enhanced cell line development platform offers an evolved approach to widely accepted cloning approaches.

Leveraging the elements of transposase technology in a single vector and using platform cloning approaches simplifies the selection process. Advanced and widely accepted industry standard analytical characterization processes positions an AbZelectPRO™ clone that is de-risked, resulting in a more robust development program, providing regulated bodies the confidence to approve products developed using the AbZelectPRO™ approach. In our discussion, we’ll describe the AbZelectPRO™ platform, demonstrate how it enables a DNA sequence to a research cell bank (RCB), show the utility in various protein expression constructs, and compare the benefits of random integration with semi-targeted approaches to build cell lines.